Board Certified Telehealth 20 Yrs Experience Carissa Strouse, NP Nurse Practitioner Preventive Care & Obesity Medicine Over 15 years in cardiovascular and preventive care, specializing in obesity medicine
Disclosures The authors Saman Tauqir, Momina Israr, Bushra Rauf, Muhammad Omar Malik, Syed Hamid Habib, Fawad Ali Shah, Muhammad Usman, Muhammad Asif Raza, Inayat Shah, Haroon Badshah, Ehtesham Ehtesham, and Mohsin Shah have nothing to disclose
The first is tirzepatide, a dual GIP/GLP-1 receptor agonist that targets both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 pathways simultaneously
I can use it easily at home, and the effects last, keeping my appetite in check
Some plans require documented weight loss (often 5% at six months) to continue authorization beyond the initial period
Personalization Matters Most Every body is different